Research

Estimates

SA Earngings
MB Earnings
Yahoo Earnings
CNBC Earnings
Barrons Earnings

Ratings

SA Ratings
MB Ratings
BC Ratings
TR Ratings
Fidelity

Short Interest

MB Shorts
Quandl

Smart Money

MB Institutional
Gurus

Options

BC Options Ratio

Financials

GuruFocus Summary

Social

Stocktwits
MB Social
SocialSentiment.com
Twitter
Yahoo
Facebook
Reuters
Google

Misc

Tickeron
Ycharts NAV +/-

Recursion Pharmaceuticals, Inc. Class A Common Stock | RXRX

AI Analysis of Recursion Pharmaceuticals, Inc. Class A Common Stock

Recursion Pharmaceuticals is down a bit on the day, funds flowing out kept the price down -1.66% since yesterday. RXRX is near a weak support line. We'll see if it bounces off or heads lower. Recursion Pharmaceuticals hasn't been that impressive in terms of its 3 month momentum, we'll see if it can turn things around and start heading up or continue its slide down.

If we get a reversal off of support and Recursion Pharmaceuticals starts moving up, it can probably get to $3.96 at which point it'll need to break through that resistance level in order to keep moving higher. There aren't very obvious support levels beneath this point. So put those stop losses on, this thing has room to fall if buyers don't come in at this level.


Last analyzed on 2026-07-23

Research

Estimates

SA Earngings
MB Earnings
Yahoo Earnings

Ratings

SA Ratings
MB Ratings
BC Ratings
TR Ratings
Fidelity

Short Interest

MB Shorts
Quandl

Smart Money

MB Institutional
Gurus

Options

BC Options Ratio

Financials

GuruFocus Summary

Social

MB Social
SocialSentiment.com
Twitter
Yahoo
Facebook
Reuters
Google

Misc

Tickeron
Ycharts NAV +/-